Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $182.07 | 9 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $103.68 | 6 | $0 (2021) |
| IDORSIA PHARMACEUTICALS US INC | $37.33 | 1 | $0 (2023) |
| Abbott Laboratories | $23.98 | 1 | $0 (2024) |
| Horizon Therapeutics plc | $17.08 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23.98 | 1 | Abbott Laboratories ($23.98) |
| 2023 | $37.33 | 1 | IDORSIA PHARMACEUTICALS US INC ($37.33) |
| 2021 | $33.45 | 2 | Horizon Therapeutics plc ($17.08) |
| 2020 | $72.71 | 4 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($72.71) |
| 2019 | $14.60 | 1 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($14.60) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/12/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $23.98 | General |
| Category: Heart Failure | ||||||
| 05/15/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $37.33 | General |
| Category: INSOMNIA | ||||||
| 07/15/2021 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: KRYSTEXXA | ||||||
| 01/08/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: Gastroenterology | ||||||
| 09/15/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/03/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/12/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/15/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/26/2019 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: GASTROENTEROLOGY | ||||||
About Dr. Mark Thompson, MD
Dr. Mark Thompson, MD is a Neonatal-Perinatal Medicine healthcare provider based in Tripler Amc, Hawaii. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1326011099.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Thompson, MD has received a total of $182.07 in payments from pharmaceutical and medical device companies, with $23.98 received in 2024. These payments were reported across 9 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($182.07).
Practice Information
- Specialty Neonatal-Perinatal Medicine
- Location Tripler Amc, HI
- Active Since 02/10/2006
- Last Updated 07/08/2007
- Taxonomy Code 2080N0001X
- Entity Type Individual
- NPI Number 1326011099
Products in Payments
- XIFAXAN (Drug) $103.68
- QUVIVIQ (Drug) $37.33
- CARDIOMEMS (Device) $23.98
- KRYSTEXXA (Biological) $17.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.